Medical Marijuana Cards in VA - Rethink-Rx
Does Marijuana Kill Cancer?

Does Medical Marijuana Kill Cancer?

The Emerging Evidence on Cannabis and its Potential in Fighting Cancer

The relationship between cannabis and cancer has long been a topic of debate and research. While the medicinal properties of cannabis have been acknowledged for centuries, its potential in the fight against cancer has gained increasing attention in recent years. While it’s essential to emphasize that cannabis is not a cure for cancer, there is a growing body of evidence suggesting that certain components of cannabis, specifically cannabinoids, may have anti-cancer properties. In this article, we will explore the evidence that supports the idea that cannabis can have a role in killing cancer cells, although much more research is needed to fully understand its potential.

Cannabis and Cancer: A Historical Perspective

Cannabis has been used for its medicinal properties dating back thousands of years, with references to its use in treating various ailments found in ancient texts from different cultures. However, its potential as a cancer treatment was not explored until more recent times. The discovery of the endocannabinoid system in the 1990s revolutionized our understanding of how cannabinoids interact with the human body, leading to increased interest in the potential therapeutic applications of cannabis, including its role in cancer treatment.

Cannabinoids and Their Effects on Cancer Cells

Cannabinoids are the active compounds found in cannabis. The two primary cannabinoids that have been studied extensively are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is known for its psychoactive effects, while CBD is non-psychoactive and is commonly used for various therapeutic purposes. Studies have shown that both THC and CBD may have anti-cancer properties, although their mechanisms of action differ. Some people also have developed an interest in cannabis-based therapy, such as Rick Simpson Oil, a high-THC extract as an anti-cancer therapy.

  1. Anti-proliferative Effects

One of the most well-documented effects of cannabinoids on cancer cells is their ability to inhibit cell proliferation. Numerous studies have shown that cannabinoids, particularly CBD, can slow down the growth of various types of cancer cells. For example, a 2011 study published in the journal Molecular Cancer Therapeutics found that CBD induced cell death and inhibited the growth of breast cancer cells in laboratory settings. Similarly, research has shown that cannabinoids can hinder the proliferation of prostate, lung, colon, and brain cancer cells.

  1. Apoptosis Induction

Apoptosis is a process of programmed cell death that plays a crucial role in preventing the uncontrolled growth of cancer cells. Some studies have suggested that cannabinoids can induce apoptosis in cancer cells. Research published in the Journal of Molecular Medicine in 2006 demonstrated that THC triggered apoptosis in glioma cells, a type of brain cancer. Other studies have reported similar findings in various cancer cell lines.

  1. Anti-Angiogenic Effects

Angiogenesis is the process by which new blood vessels form to supply nutrients to growing tumors. Inhibition of angiogenesis is a promising strategy for cancer treatment. Cannabinoids, including both THC and CBD, have been shown to possess anti-angiogenic properties. A 2003 study in the journal Cancer Research found that cannabinoids reduced the formation of blood vessels in glioblastoma, a highly aggressive brain cancer.

  1. Immune System Modulation

Cannabinoids can also modulate the immune system, potentially enhancing the body’s ability to recognize and attack cancer cells. This is an exciting area of research, as an improved immune response could be a key factor in cancer treatment. While the precise mechanisms are not fully understood, studies have shown that cannabinoids can influence the activity of immune cells, such as T-cells and natural killer cells, which play crucial roles in immune surveillance against cancer.

Cannabis and Preclinical Studies

Preclinical studies using cell cultures and animal models have provided valuable insights into the potential of cannabis in cancer treatment. These studies have contributed to our understanding of how cannabinoids may affect cancer cells and have laid the groundwork for clinical research.

For instance, a study published in the journal Oncotarget in 2019 explored the effects of a combination of THC and CBD on pancreatic cancer cells. The researchers found that this combination reduced the viability of cancer cells and hindered tumor growth in mice. Another study published in the journal Molecular Cancer Therapeutics in 2007 investigated the use of THC and CBD in combination with radiation therapy for the treatment of glioblastoma. The results suggested that cannabinoids enhanced the effectiveness of radiation therapy in reducing tumor growth.

Cannabis and Clinical Trials

While preclinical studies have provided encouraging results, it is essential to transition to clinical trials to evaluate the safety and efficacy of cannabis in cancer treatment in humans. Several clinical trials have been conducted or are ongoing to assess the potential of cannabinoids in various cancer types.

  1. Synthetic Cannabinoids for Cancer-Related Symptoms

Many clinical trials have focused on using synthetic cannabinoids, such as dronabinol and nabilone, to manage cancer-related symptoms. These symptoms can include nausea and vomiting induced by chemotherapy, pain, and appetite loss. Synthetic cannabinoids have been approved by regulatory authorities for use in these contexts, and their effectiveness is well-documented.

  1. Investigating Cannabis Extracts and Combinations

Some clinical trials have explored the use of whole-plant cannabis extracts or combinations of cannabinoids, such as THC and CBD, for cancer-related symptoms. These studies aim to determine if cannabis extracts can provide a more comprehensive and potentially more effective treatment compared to synthetic cannabinoids. While some trials have shown promising results, the variability in cannabis formulations and dosages can make it challenging to draw definitive conclusions.

  1. Investigating Cannabinoids as an Adjunct to Conventional Therapies

A particularly interesting area of clinical research is the potential of cannabinoids as adjuncts to conventional cancer therapies, such as chemotherapy and radiation. A study published in the European Journal of Internal Medicine in 2018 investigated the use of cannabinoids in combination with standard treatment for patients with glioblastoma. The results indicated that the addition of cannabinoids led to a higher one-year survival rate compared to standard treatment alone.

Cannabis and Its Potential Limitations

While the evidence on cannabis and its potential in killing cancer cells is intriguing, it’s crucial to acknowledge the limitations and challenges associated with this area of research:

  1. Lack of Clinical Consensus: Despite promising preclinical data and some positive clinical trial results, there is no consensus within the medical community regarding the use of cannabis as a primary treatment for cancer. More high-quality clinical trials are needed to establish its safety and efficacy conclusively.
  2. Heterogeneity of Cannabis Products: Cannabis products can vary significantly in terms of cannabinoid content, ratios of THC to CBD, and other compounds present in the plant. This variability can make it difficult to standardize treatment and determine the optimal dosage.
  3. Legal and Regulatory Challenges: The legal status of cannabis varies from country to country, which can create barriers to research and access for patients. Additionally, regulatory hurdles can slow down the development of cannabis-based therapies.
  4. Potential Side Effects: Cannabis can have side effects, including psychoactive effects, dizziness, dry mouth, and changes in mood. These side effects can affect the quality of life for cancer patients, especially when undergoing treatment.
  5. Lack of Long-Term Data: Many cancer treatments require long-term follow-up to assess their impact on survival rates and quality of life. As the use of cannabis in cancer treatment is a relatively recent development, long-term data are limited.
  6. Ethical and Social Considerations: The use of cannabis in cancer treatment also raises ethical and social considerations, including potential misuse and dependency issues.


The relationship between cannabis and cancer is a complex and evolving one. While there is growing evidence to suggest that certain cannabinoids may have anti-cancer properties, it is important to stress that cannabis is not a cure for cancer. Instead, it may have a role as an adjunct therapy, particularly in managing cancer-related symptoms and potentially enhancing the effectiveness of conventional treatments.

The evidence that cannabis can kill cancer cells is primarily based on preclinical studies and some promising results from clinical trials. However, more high-quality research is needed to determine the safety and efficacy of cannabis-based treatments fully. As the legal and regulatory landscape surrounding cannabis continues to evolve, we can expect more research to shed light on its potential role in the fight against cancer. In the meantime, it is crucial for patients to work closely with healthcare professionals to make informed decisions about their treatment options, considering the current state of scientific knowledge and the individual circumstances of each case.